Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Entasis Therapeutics Holdings Inc. (ETTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.9200-0.0500 (-2.54%)
At close: 04:00PM EST
1.9200 0.00 (0.00%)
After hours: 05:20PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.9700
Open1.9500
Bid1.8800 x 1300
Ask1.9800 x 1000
Day's Range1.8981 - 1.9700
52 Week Range1.7600 - 3.8800
Volume65,909
Avg. Volume301,453
Market Cap91.464M
Beta (5Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)-1.1360
Earnings DateMar 21, 2022 - Mar 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.25
  • GlobeNewswire

    Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022

    WALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the Company will be participating in the H.C. Wainwright BioConnect 2022 investor conference, to be held virtually from January 10-13, 2022. Details for the event and management’s participation are as follows: H.C. Wainwright BioConnect 2022Dates: January

  • Simply Wall St.

    How Many Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) Shares Do Institutions Own?

    If you want to know who really controls Entasis Therapeutics Holdings Inc. ( NASDAQ:ETTX ), then you'll have to look at...

  • GlobeNewswire

    Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

    Management to host a conference call on November 4, 2021 at 8:00am ETSulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints from landmark Phase 3 ATTACK trialRobust dataset builds compelling case for SUL-DUR which if approved, could become the first, uniquely differentiated and life-saving treatment option for patients with Acinetobacter infectionsPreparing for commercialization ahead of NDA submission in mid-2022, under the leadership of newly appointed Chief Commercial Of

Advertisement
Advertisement